FY2018 Earnings Forecast for Teva Pharmaceutical Industries Ltd Issued By Oppenheimer (TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Analysts at Oppenheimer raised their FY2018 EPS estimates for shares of Teva Pharmaceutical Industries in a research note issued to investors on Wednesday, October 17th, Zacks Investment Research reports. Oppenheimer analyst E. Rajavelu now anticipates that the company will earn $2.66 per share for the year, up from their prior forecast of $2.64. Oppenheimer has a “Hold” rating on the stock.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, November 1st. The company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.53 by $0.11. The company had revenue of $4.53 billion for the quarter, compared to analysts’ expectations of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. Teva Pharmaceutical Industries’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.00 earnings per share.

Other analysts have also issued research reports about the company. Mizuho reaffirmed a “buy” rating and issued a $28.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 16th. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Tuesday, August 7th. Goldman Sachs Group raised Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective for the company in a research note on Monday, October 1st. Morgan Stanley increased their price objective on Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, August 3rd. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $25.00 price objective on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 16th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $21.58.

TEVA traded down $0.39 during midday trading on Thursday, hitting $23.45. The stock had a trading volume of 6,637,061 shares, compared to its average volume of 10,918,274. The firm has a market cap of $24.13 billion, a P/E ratio of 7.39, a P/E/G ratio of 7.28 and a beta of 0.77. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a 1 year low of $11.44 and a 1 year high of $25.96.

Institutional investors and hedge funds have recently bought and sold shares of the business. First Republic Investment Management Inc. raised its holdings in Teva Pharmaceutical Industries by 30.1% in the second quarter. First Republic Investment Management Inc. now owns 20,110 shares of the company’s stock worth $489,000 after purchasing an additional 4,657 shares in the last quarter. Global Financial Private Capital LLC increased its holdings in shares of Teva Pharmaceutical Industries by 92.2% during the second quarter. Global Financial Private Capital LLC now owns 23,632 shares of the company’s stock valued at $575,000 after acquiring an additional 11,335 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Teva Pharmaceutical Industries by 26.8% during the second quarter. Sei Investments Co. now owns 162,241 shares of the company’s stock valued at $3,946,000 after acquiring an additional 34,305 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 553.3% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 22,361 shares of the company’s stock valued at $544,000 after acquiring an additional 18,938 shares in the last quarter. Finally, Toronto Dominion Bank bought a new position in shares of Teva Pharmaceutical Industries during the second quarter valued at $669,000. Institutional investors and hedge funds own 65.10% of the company’s stock.

In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the transaction, the insider now owns 2,376 shares in the company, valued at $56,334.96. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Richard Daniell sold 2,488 shares of the stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total value of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,531 shares of company stock valued at $152,749. 0.43% of the stock is owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply